Hexarelin Dosage Chart
Clinic-convention short-cycle protocol, with cortisol and prolactin caveats that distinguish hexarelin from ipamorelin.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
Hexarelin is a potent ghrelin-receptor agonist discussed in the literature for GH-secretagogue biology and metabolic/cardiovascular hypotheses. Clinic protocols often keep use short because of cortisol/prolactin and waning-response concerns, but the cited literature does not establish the 100 mcg dose or a 4-week cycle.
Hexarelin at a Glance
| Typical dose | 100 mcg subQ |
|---|---|
| Frequency | 1–2× per day |
| Cycle length | 4 weeks on, 4 weeks off (clinic convention; not trial-derived) |
| Typical max | 200–300 mcg/day |
| FDA status | Not FDA-approved. Compounded. |
| Source quality | Background diabetes/heart-disease review; off-label dosing is practitioner/vendor-derived. |
Hexarelin Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for Hexarelin. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 5 mg | 2.5 mL | 2 mg/mL (200 mcg per 0.1 mL) |
|
Hexarelin Dosing by Use Case
Commonly cited protocols vary by what Hexarelin is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| GH stimulation (high potency, short cycle) | 100 mcg | 1–2× daily | 4 weeks on, 4 weeks off | Clinic-convention cycle intended to limit waning response; not established by the cited review. |
Stacking Hexarelin
In clinic/vendor protocols, hexarelin is usually presented as a short-course option because of its potency and cortisol/prolactin concerns. If used with another GH-releasing peptide, that pairing is practitioner-derived; the cited review does not establish a stack.
Where these numbers come from
The cited PubMed paper is a diabetes and diabetes-associated heart-disease review that discusses ghrelin/hexarelin biology, GH-secretagogue effects, and metabolic/cardiovascular hypotheses; it is not a human dosing trial for this protocol. The 100 mcg subQ dose, 1-2x/day schedule, 4-week cycling, and desensitization-management language are clinic/vendor convention, not doses derived from that paper or an FDA label. Cortisol/prolactin and waning-response concerns are presented here as safety/practice context rather than source-established dosing rules.
Hexarelin is a potent ghrelin-receptor secretagogue; cortisol/prolactin and waning-response concerns are reasons clinics limit use, but human dosing evidence is thin.
- •Cortisol and prolactin elevation are reported concerns for less-selective GH secretagogues; dose-specific risk at this chart's protocol is not established by the cited review.
- •Short cycles are used in practice because response may wane with continuous use; this chart does not cite a human cycling trial.
- •Reported side effects: water retention, transient blood pressure changes, joint pain.
- •Not FDA-approved.
- •Active or recent malignancy
- •Untreated hyperprolactinemia
- •Cushing's syndrome or other cortisol disorders
- •Pregnancy or breastfeeding
Hexarelin Dosing FAQ
In clinic practice, hexarelin is generally framed as a brief high-potency option rather than a continuous maintenance peptide. This chart does not cite human outcome data showing it is superior to ipamorelin.
This chart uses 4 weeks on followed by a 4-week break as a clinic-convention cycle. The cited review does not establish that duration, and longer continuous cycles are usually avoided because response may wane.
Sources
Related Dosage Charts
Want the full Hexarelin guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for Hexarelin therapy.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.